Royalty Pharma reports second quarter 2026 results
Royalty Pharma plc (RPRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Press Release August 5, 2026 R oyalty Pharma reports second quarter 2026 results Portfolio Rece ipts growth o f 6% to $773 million ; Royalty Receipts growth of 14% Net cash provided by operating activities of $728 million Raised f ull year 2026 guidance: Portfolio Receipts expect
How this was made
The 30-second read
Why it matters
The key tradable items are Q2 Portfolio Receipts and Royalty Receipts growth, plus the raised 2026 Portfolio Receipts range and stated assumptions (FX impact, interest paid, and exclusion of future transactions).
Market read
A same-day guidance raise with concrete numeric ranges and Q2 cash flow metrics is a direct input to near-term valuation and positioning.
What to watch
Milestones and other contractual receipts fell year over year in Q2, which could reintroduce volatility if royalty receipts growth moderates.
Portfolio Receipts increased by 6% to $773 million; Royalty Pharma raised full year 2026 Portfolio Receipts guidance to $3,400 million to $3,500 million.
Royalty Receipts grew 14% to $768 million, Adjusted EBITDA increased 16% to $736 million, and the company raised Portfolio Receipts guidance. Portfolio Receipts growth was lower at 6% because Milestones and other contractual receipts fell 91% versus a prior-year one-time distribution.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Portfolio Receiptsother | $773M | – | 6% |
| Royalty Receiptsother | $768M | – | 14% |
| Milestones and other contractual receiptsother | $5M | – | (91)% |
| Net cash provided by operating activitiesGAAP | $728M | – | 100% |
| Adjusted EBITDAnon-GAAP | $736M | – | 16% |
| Portfolio Cash Flownon-GAAP | $736M | – | 15% |
| Payments for operating and professional costsother | ($37) million | – | – |
| Payments for operating and professional costs as a percentage of Portfolio Receiptsother | 4.8% | – | – |
| Interest (paid)/received, netother | ($0) million | – | – |
| Weighted average Class A ordinary shares outstanding - dilutedother | 557M | – | (1)% |
| Capital Deploymentother | $349M | – | – |
| Purchases of available for sale debt securities, six months ended June 30other | — | – | – |
| Acquisitions of financial royalty assets, six months ended June 30other | ($703) million | – | – |
| Development-stage funding payments, six months ended June 30other | ($123) million | – | – |
| Milestone payments, six months ended June 30other | ($50) million | – | – |
| Contributions from legacy non-controlling interests - R&D, six months ended June 30other | — | – | – |
| Capital Deployment, six months ended June 30other | ($877) million | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Cystic fibrosis franchiseNo product-specific driver provided. | $194M | – | 0% |
| TysabriNo product-specific driver provided. | $67M | – | 19% |
| TrelegyNo product-specific driver provided. | $58M | – | 3% |
| TremfyaIdentified as a primary driver of the increase in Royalty Receipts. | $57M | – | 53% |
| EvrysdiRoyalty Receipts included the benefit of the additional royalties acquired in December 2025. | $47M | – | 42% |
| VoranigoIdentified as a primary driver of the increase in Royalty Receipts. | $46M | – | 72% |
| XtandiNo product-specific driver provided. | $44M | – | 6% |
| ImbruvicaDeclines from Imbruvica partially offset Royalty Receipts growth. | $36M | – | (16)% |
| Cabometyx/CometriqNo product-specific driver provided. | $23M | – | 12% |
| ImdelltraIdentified as a primary driver of the increase in Royalty Receipts. | $17M | – | n/a |
| TrodelvyNo product-specific driver provided. | $14M | – | 36% |
| SpinrazaNo product-specific driver provided. | $11M | – | (11)% |
| AmvuttraNo product-specific driver provided. | $9M | – | n/a |
| PromactaDeclined due to U.S. generic competition. | $8M | – | (75)% |
| Other products (5)No product-specific driver provided. | $139M | – | 28% |
full year 2026 outlook
- RevenuePortfolio Receipts: $3,400 million to $3,500 million
- Operating expensesPayments for operating and professional costs: 5.5% to 6.5% of Portfolio Receipts
- NoteExpected Royalty Receipts growth: 7% to 10% in 2026.
- NoteInterest paid: $350 million to $360 million.
- NoteEstimated foreign exchange impact: approximately +1% to Portfolio Receipts.
- NoteInterest paid in the third quarter of 2026: approximately $175 million.
- NoteInterest paid in the fourth quarter of 2026: a de minimis amount.
- NoteGuidance assumes repayment of the $380 million term loan in July 2026 and no additional debt financing in 2026.
- NoteGuidance excludes new transactions and borrowings announced after the date of the release and contributions from transactions announced subsequent to the date of the press release.
Capital returns
- Quarterly dividend: $0.235 per share, equating to $135 million in dividends and distributions in the second quarter of 2026.
- Repurchased approximately 0.9 million Class A ordinary shares for $45 million in the second quarter of 2026.
- Repurchased two million Class A ordinary shares for $96 million for the first six months of 2026.
What drove it
- Royalty Receipts growth was primarily driven by Tremfya, Voranigo, Imdelltra and Evrysdi.
- Portfolio Receipts growth reflected the Royalty Receipts increases, partially offset by lower Milestones and other contractual receipts.
- Milestones and other contractual receipts declined due to a one-time distribution received in the prior-year period.
- Payments for operating and professional costs are expected to decrease as a percentage of Portfolio Receipts compared with 8.9% in 2025, primarily due to extinguishment of the management fee following the internalization transaction on May 16, 2025.
- Second-quarter Capital Deployment consisted primarily of royalty funding for daraxonrasib and R&D funding for JNJ-4804 and litifilimab.
Concerns
- Milestones and other contractual receipts declined 91% to $5 million, reflecting a one-time distribution received in the prior-year period.
- Promacta Portfolio Receipts declined 75% due to U.S. generic competition.
- Imbruvica Portfolio Receipts declined 16%.
- Guidance assumes no major unforeseen adverse events or changes in foreign exchange rates.
What to watch
- Delivery against full year 2026 Portfolio Receipts guidance of $3,400 million to $3,500 million and expected Royalty Receipts growth of 7% to 10%.
- The expected approximately $175 million of interest paid in the third quarter of 2026.
- Progress of daraxonrasib after the FDA accepted its NDA for review and the EMA started its accelerated review.
- The royalty on AstraZeneca's cliramitug, acquired in July 2026 for up to $425 million, including $125 million upfront.
- Deployment under the up to $1.7 billion of announced new transactions as of August 4, 2026.
Balance sheet and cash flow
- Cash and cash equivalents as of June 30, 2026: $812 million.
- Total debt with principal value as of June 30, 2026: $9.2 billion.
- Repaid the $380 million term loan upon maturity in July 2026.
- Net cash provided by operating activities was $728 million in the second quarter of 2026.
- Royalty Pharma collected interest of $5 million on its cash and cash equivalents in the second quarter of 2026.
- Capital Deployment was $349 million in the second quarter of 2026.
- As of August 4, 2026, announced new transactions of up to $1.7 billion and Capital Deployment of $1.1 billion.
Analysis
Royalty Pharma reported second-quarter Portfolio Receipts of $773 million, up 6% from $727 million, while Royalty Receipts grew 14% to $768 million. The difference reflects Milestones and other contractual receipts of $5 million, down 91% from $56 million because the prior-year period included a one-time distribution. The company raised full year 2026 Portfolio Receipts guidance to $3,400 million to $3,500 million from $3,325 million to $3,450 million.
Royalty Receipts growth was led by Tremfya, Voranigo, Imdelltra and Evrysdi. Tremfya increased 53% to $57 million, Voranigo increased 72% to $46 million, and Evrysdi increased 42% to $47 million, with Evrysdi benefiting from additional royalties acquired in December 2025. Offsetting portfolio pressure came from Promacta, down 75% to $8 million due to U.S. generic competition, and Imbruvica, down 16% to $36 million.
Cash generation improved materially. Net cash provided by operating activities was $728 million, compared with $364 million, while Adjusted EBITDA increased 16% to $736 million and Portfolio Cash Flow increased 15% to $736 million. Payments for operating and professional costs were $37 million and represented 4.8% of Portfolio Receipts. The company expects those costs to be 5.5% to 6.5% of full-year Portfolio Receipts, compared with 8.9% in 2025, primarily due to the extinguishment of the management fee following the May 16, 2025 internalization transaction.
Capital allocation remained active. Capital Deployment was $349 million in the quarter and $877 million for the first six months of 2026. As of August 4, 2026, the company had announced new transactions of up to $1.7 billion and Capital Deployment of $1.1 billion. In July, Royalty Pharma acquired a portion of Neurimmune AG's royalty interest in AstraZeneca's cliramitug for up to $425 million, including $125 million upfront.
Liquidity at June 30 included $812 million of cash and cash equivalents and $9.2 billion of total debt with principal value. The company repaid its $380 million term loan in July 2026. It returned capital through a $0.235 per-share quarterly dividend, equating to $135 million, and $45 million of second-quarter share repurchases. Guidance assumes interest paid of $350 million to $360 million for 2026, including approximately $175 million in the third quarter, no additional debt financing in 2026, and an estimated foreign exchange impact of approximately +1% to Portfolio Receipts.
Management, verbatim
Royalty Pharma delivered strong second quarter results with Royalty Receipts growth of 14%.
Pablo Legorreta, Chief Executive Officer and Chairman of the Board
Not in the filing
stated, not guessed- GAAP revenue, gross profit or gross margin were not provided in the supplied filing text.
- GAAP operating income, GAAP net income, GAAP diluted EPS, and non-GAAP EPS were not provided in the supplied filing text.
- Prior-quarter comparisons for Portfolio Receipts, Royalty Receipts, product-level Portfolio Receipts, cash flow measures, and diluted shares were not provided.
- A previous earnings release outlook section was not provided, so no reported actual-versus-prior-guidance comparison is included.
- Balance-sheet comparative cash and debt figures were not provided.
- Free cash flow was not reported.
- Product-level drivers were not separately provided for the cystic fibrosis franchise, Tysabri, Trelegy, Xtandi, Cabometyx/Cometriq, Trodelvy, Spinraza, Amvuttra, and Other products (5).
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Royalty Pharma reports quarterly results and updates full-year guidance via an SEC 8-K with an attached press release.
Ticker impact
Royalty Pharma raised full-year 2026 Portfolio Receipts guidance to $3,400 million to $3,500 million and reported Q2 Portfolio Receipts of $773 million.
Likely positive bias for the next session as traders reprice 2026 top-line expectations and cash generation.
The filing discloses a same-day guidance increase with specific numeric ranges, alongside Q2 results and liquidity/cash flow metrics.
Market effects
Reinforces demand for royalty financing models in life sciences, potentially supporting sentiment toward other royalty and specialty pharma finance peers.
Primarily US-listed biotech/healthcare investor sentiment via Nasdaq-listed issuer guidance update.
FDA/EMA review and EU approvals mentioned are global, but the tradable catalyst here is RPRX’s own guidance and cash flow.
Counterpoint
Portfolio Receipts guidance is explicitly excluding contributions from future transactions, so upside may be capped if deal pipeline execution slips.
Key entities
- companyRoyalty Pharma plc
Nasdaq-listed royalty financing company reporting Q2 2026 results and raising full-year 2026 Portfolio Receipts guidance.
- regulatorFDA
Referenced for accelerated review acceptance of a development-stage NDA in the portfolio update section.
- regulatorEMA
Referenced for accelerated review start related to a development-stage NDA in the portfolio update section.
